kynurenine and AIDS Dementia Complex

kynurenine has been researched along with AIDS Dementia Complex in 12 studies

Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.

AIDS Dementia Complex: A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)

Research

Studies (12)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Cognitive Gross Motor Function Domain Z-Score

The cognitive gross motor function is a age and education adjusted z score of Timed Gait (TIG). The outcome is the 24 week change of cognitive gross motor function domain z-scores (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Cognitive Performance Compared to Baseline

"Th cognitive performance is measured by NPZ-8. NPZ-8 is defined as the average of age and education adjusted z-scores of eight neuropsychological tests subcomponents in the neuropsychological test battery. These eight tests are:~Grooved Pegboard Dominant Hand (GPD)~Grooved Pegboard Non-dominant hand (GPN)~Choice Reaction Time (CRT)~Sequential Reaction Time (QRT)~Timed Gait (TIG)~Trail Making Part A (TMA)~Trail Making Part B (TMB)~Symbol Digit (SYD) The primary outcome is NPZ-8 score at week24 - NPZ-8 score at baseline." (NCT00361257)
Timeframe: At baseline and week 24

Change in Fine Motor Function Domain Z-Score

The fine motor function domain score is an average of age, sex, education, and African-American ethnicity adjusted z scores of Grooved Pegboard Dominant Hand (GPD) and Grooved Pegboard Non-dominant hand (GPN). The outcome is a 24 week change of the fine motor function domain z-score (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Fine Motor/Nonverbal Function Domain Z-Score

The fine motor/nonverbal function domain score is a age and education adjusted z score of Symbol Digit Test (SYD) The outcome is the 24 change of fine motor/nonverbal function domain z-score (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Frontal Systems Function Domain Z-Score

The frontal systems function domain score is the average of age and education adjusted z scores of Stroop Color Interference Test (CTP) and interference task (STP). The outcome is the 24 week change of frontal systems function domain z-score (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Global Deficit Z-Score (GDS)

GDS on the test battery is the simple average of all 14 individual deficit scores in the test battery, including Time Gait, Grooved Pegboard Test for the dominant and non-dominant hands, Trail Making Test parts A and B, Symbol Digit Test, simple and sequential reaction time - CalCAP, Hopkins Verbal Learning Test (Revised)- Learning, Delayed Recall and Recognition trials, and Stroop Color Interference Test-color, word, and interference tasks. The outcome is the 24 week change of GDS Z-score (24 week-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Information Processing Function Domain Z-Score

The information processing function domain score is the average of age and education adjusted z scores of simple and sequential reaction time - CalCAP. The outcome is the 24 week change of information processing function domain z-scores (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Psychomotor Function Domain Z-Score

The psychomotor function domain score us the average of age, sex, education, and African-American ethnicity adjusted z scores of Trail Making Part A (TMA) and Trail Making Part B (TMB). The outcome is the 24 week change of psychomotor function domain z-scores (week24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Change in Verbal Memory Domain Z-Score

The verbal memory domain score is the average of age and education adjusted z scores of Hopkins Verbal Learning Test- Revised, Learning and Delayed Recall. The outcome is the 24 week change of verbal memory domain z-scores (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Changes in Alternate Frontal Systems Z-Score

The alternate frontal systems was defined as a mean of age and education adjusted z score of Interference task, and age, sex, education, and African-American ethnicity adjusted z score of Trail Making Part B. The outcome was the 24 week change in alternate frontal systems z-score (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Changes in Alternate Psychomotor Function Z-Score

The alternate psychomotor function is defined as the mean of age, sex, education, and African-American ethnicity adjusted z scores of Trail Making Part A (TMA), and age and education adjusted z score of Symbol Digit (SYD). The outcome is the 24 week change in alternate psychomotor function z-score (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Changes in Alternate Verbal Memory Z-Score

The alternate verbal memory was defined as a mean of age and education adjusted z score of trials 1 to 3 and delayed recall tests. The outcome is the 24 week change in alternate verbal memory z-score (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Changes in Cluster of Differentiation 4 (CD4) Cell Counts (24 Weeks)

The outcome was the 24 week change in CD4 cell count (week 24-baseline). (NCT00361257)
Timeframe: At baseline and weeks 24

Changes in Cluster of Differentiation 8 (CD8) Cell Counts (24 Weeks)

The outcome was the 24 week change of CD8 cell counts (week 24-baseline). (NCT00361257)
Timeframe: At baseline and week 24

Changes in Markers of Oxidative Stress (Unit = Pixels/mm2 Only)

Protein marker of oxidative stress (Neurofilament heavy polypeptide). The outcome is the 24 week change (week 24-baseline). (NCT00361257)
Timeframe: At pre-entry and Week 24

Changes in Medication Management Test (Modified)

The medication management test (modified) is designed to assess participants' medication management ability and their own medications and management. It's the number of how many times participants correctly answered 16 questions. The score ranges between 0 and 16, and higher score indicates better medication management. (NCT00361257)
Timeframe: At baseline and weeks 24

Change in Investigator's Clinical Global Impression Score (ICGIS)

"Clinicians were asked to rate their overall impression about the clinical improvement or worsening of his/her study participants. They can choose from the following 7 levels: (0) No Change, (1) Mild Improvement, (2) Moderate Improvement, (3) Marked Improvement, (4) Mild Worsening, (5) Moderate Worsening, and (6) Marked Worsening.~For the analysis, we simplified the outcome into the following 3 levels: (0) worsened, (1) No Change, and (2) Improved." (NCT00361257)
Timeframe: At week 24

Change in Karnofsky Performance Score

"The original Karnofsky performance score is 11 level score which ranges between 0 to 100. The score 100 means normal and 0 means death; therefore, higher score means higher ability to perform daily tasks.~For the analysis, a new dichotomous variable (no change/worse vs. better at 24 weeks compared to baseline) was created." (NCT00361257)
Timeframe: At baseline and week 24

Change of HIV Plasma RiboNucleic Acid (RNA) Viral Load

The original scale of HIV RNA viral load is between 30 copies/mL to infinitive. The minimum score of 30 is the lowest detectable value. The summary table categorized this continuous value to a dichotomous variable (<30 copies/mL and >= 30 copies/mL). (NCT00361257)
Timeframe: At baseline and week 24

Changes in Instrumental Activities of Daily Living Questionnaire

The Instrumental Activities of Daily Living (IADL) questionnaire is designed to learn more about how subjects are able to perform common tasks. There are 16 common tasks. For each task, if the score at the time of evaluation is worse than the best in the past, an indicator of 1 is given. Otherwise, the indicator is 0. The overall IADL score is a sum of 16 indicators divided by 16; therefore, the range is between 0 and 1 and the lower score is better. The 24-week change of IADL score was changed into a categorical variable (no change/worse vs. better) at week 24 compare to baseline. (NCT00361257)
Timeframe: At baseline and week 24

Changes in Markers of Oxidative Stress and Immune Activation (Unit=pg/mL Only)

Protein markers of oxidative stress (Protein carbonyls) and markers of immune activation (TNF-a, IL-6,CXCL8, Hepatocyte growth factor, Osteopontin, sFAS, sFAS ligand, and CXCL12). For all markers, the outcome is the 24 week change (week 24-baseline). (NCT00361257)
Timeframe: At pre-entry and Week 24

Changes in Neurotransmitter Levels (Unit = uM Only)

Neurotransmitter levels (Glutamate, Tryptophan, Anthranilic Acid, Quinolinic Acid, Kynurenin, and 3-Hydroxykynurenine). The outcome is the 24 week change (week 24-baseline). (NCT00361257)
Timeframe: At pre-entry and Week 24

Changes in Protein Markers of Oxidative Stress (Unit = Counts Per Second Only)

Protein marker of oxidative stress (Ceramides, Monohexosylceramides, Dihydro Glycosyl Galceramides, and Dihexosylceramides). For all markers, the outcome is the 24 week change (week 24-baseline). (NCT00361257)
Timeframe: At pre-entry and Week 24

Number of Participants With Grade 2 or Higher Toxicity and/or Signs and Symptoms

Grade or higher means that adverse events were moderate, severe, or life-threatening, or death. Grade 2 or higher adverse events are lised in the Adverse Event section. (NCT00361257)
Timeframe: Throughout study up to week 48

Reviews

5 reviews available for kynurenine and AIDS Dementia Complex

Trials

1 trial available for kynurenine and AIDS Dementia Complex

Other Studies

6 other studies available for kynurenine and AIDS Dementia Complex